JP2018508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508215A5
JP2018508215A5 JP2017546104A JP2017546104A JP2018508215A5 JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5 JP 2017546104 A JP2017546104 A JP 2017546104A JP 2017546104 A JP2017546104 A JP 2017546104A JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5
Authority
JP
Japan
Prior art keywords
cell
car
domain
item
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508215A (ja
JP6574848B2 (ja
Filing date
Publication date
Priority claimed from GB201503742A external-priority patent/GB201503742D0/en
Application filed filed Critical
Publication of JP2018508215A publication Critical patent/JP2018508215A/ja
Publication of JP2018508215A5 publication Critical patent/JP2018508215A5/ja
Application granted granted Critical
Publication of JP6574848B2 publication Critical patent/JP6574848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546104A 2015-03-05 2016-03-04 Cd19結合ドメインを含むキメラ抗原レセプター(car) Active JP6574848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201503742A GB201503742D0 (en) 2015-03-05 2015-03-05 Chimeric antigen receptor
GB1503742.7 2015-03-05
PCT/GB2016/050574 WO2016139487A1 (en) 2015-03-05 2016-03-04 Chimeric antigen receptor (car) comprising a cd19-binding domain

Publications (3)

Publication Number Publication Date
JP2018508215A JP2018508215A (ja) 2018-03-29
JP2018508215A5 true JP2018508215A5 (enExample) 2019-03-07
JP6574848B2 JP6574848B2 (ja) 2019-09-11

Family

ID=52998440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546104A Active JP6574848B2 (ja) 2015-03-05 2016-03-04 Cd19結合ドメインを含むキメラ抗原レセプター(car)

Country Status (15)

Country Link
US (3) US10457730B2 (enExample)
EP (1) EP3265490B1 (enExample)
JP (1) JP6574848B2 (enExample)
CN (1) CN107406517B (enExample)
AU (1) AU2016227498B2 (enExample)
CA (1) CA2978381C (enExample)
DK (1) DK3265490T3 (enExample)
ES (1) ES2732067T3 (enExample)
FR (1) FR25C1040I1 (enExample)
GB (1) GB201503742D0 (enExample)
HU (2) HUE044298T2 (enExample)
PL (1) PL3265490T3 (enExample)
PT (1) PT3265490T (enExample)
TR (1) TR201909647T4 (enExample)
WO (1) WO2016139487A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877291A (zh) 2014-04-10 2021-06-01 西雅图儿童医院 (Dba西雅图儿童研究所) 基因修饰的t细胞产品、其制备方法和用途
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
HK1256087A1 (zh) 2015-08-07 2019-09-13 Seattle Children's Hospital, Dba Seattle Children's Research Institute 用於实体瘤靶向的双特异性cart细胞
US9681109B2 (en) * 2015-08-20 2017-06-13 Qualcomm Incorporated Systems and methods for configurable demodulation
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
CN107098981B (zh) * 2017-06-29 2020-05-01 青岛麦迪赛斯医疗技术有限公司 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
CN111465616B (zh) * 2017-12-06 2023-08-01 艾克隆株式会社 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3757133A4 (en) * 2018-02-11 2021-12-01 Jiangsu Hengrui Medicine Co., Ltd. ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN108794642A (zh) * 2018-07-05 2018-11-13 宁波安诺柏德生物医药科技有限公司 一种嵌合抗原细胞受体及其应用
CN110819678A (zh) * 2018-08-07 2020-02-21 上海恒润达生生物科技有限公司 一种评估cart细胞有效性的方法
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR20210125978A (ko) 2018-11-01 2021-10-19 그라셀 바이오테크놀로지스 (상하이) 컴퍼니, 리미티드 T 세포 조작을 위한 조성물 및 방법
CN109468282B (zh) * 2018-11-22 2019-06-18 青岛协和华美医学诊断技术有限公司 一种靶向cd19的嵌合抗原受体t细胞的制备方法及应用
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
JP6821230B2 (ja) * 2019-02-04 2021-01-27 国立大学法人愛媛大学 CARライブラリおよびscFvの製造方法
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
KR20210126078A (ko) 2019-02-13 2021-10-19 더 브리검 앤드 우먼즈 하스피털, 인크. 항-말초 림프절 어드레신 항체 및 그의 용도
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
EP3980450A4 (en) * 2019-06-04 2024-06-19 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
EP4021485A1 (en) 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
WO2021105988A1 (en) 2019-11-26 2021-06-03 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
US20230085724A1 (en) 2020-03-05 2023-03-23 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技(香港)有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング/ビジネス/アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体(car)
WO2022031597A1 (en) 2020-08-03 2022-02-10 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
AU2021413365A1 (en) 2020-12-30 2023-07-20 Precigen, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
CN117545771A (zh) * 2021-04-08 2024-02-09 克莱格医学有限公司 细胞免疫治疗的应用
CN117088975B (zh) * 2022-05-11 2024-06-25 东莞市朋志生物科技有限公司 抗白蛋白抗体、检测白蛋白的试剂和试剂盒
WO2023218381A1 (en) 2022-05-11 2023-11-16 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
CN116253794B (zh) * 2022-08-19 2025-04-04 首都医科大学宣武医院 一种用于car-t细胞调控的抗体及其应用
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2024246526A1 (en) 2023-05-30 2024-12-05 Autolus Limited Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2025008642A1 (en) 2023-07-05 2025-01-09 Autolus Limited Method
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
GB202316184D0 (en) 2023-10-23 2023-12-06 Autolus Ltd Method
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173654A1 (en) * 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
MX2014010183A (es) * 2012-02-22 2015-03-20 Univ Pennsylvania Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
PL2997141T3 (pl) 2013-05-13 2023-02-06 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2018508215A5 (enExample)
KR102483822B1 (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2017508466A5 (enExample)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
CN112390892B (zh) 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
JP2018527919A5 (enExample)
JP2019532625A5 (enExample)
JP2017500869A5 (enExample)
RU2017121892A (ru) Клетка
JP2015527070A5 (enExample)
JP2016520074A5 (enExample)
JP2018528776A5 (enExample)
JP2009518050A5 (enExample)
JP2019530431A5 (enExample)
JP2019535262A5 (enExample)
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
CN118843693A (zh) 靶向bcma的嵌合抗原受体及其应用
JP2022530541A (ja) Bcmaを標的とするcar t細胞及びその使用
US20250236864A1 (en) CAR LIBRARY AND scFv MANUFACTURING METHOD
WO2023193660A1 (zh) 增强型嵌合抗原受体及其应用
EP4007777B1 (en) Car t-cells against bcma for the treatment of multiple myeloma
WO2024017362A1 (zh) 靶向gprc5d和/或bcma的嵌合抗原受体及其应用
JP2020509745A5 (enExample)
JPWO2020144697A5 (enExample)